一品紅(300723.SZ):子公司獲得鹽酸溴己新注射液註冊證書
格隆匯9月15日丨一品紅(300723.SZ)公佈,公司全資子公司廣州一品紅製藥有限公司於近日收到國家藥品監督管理局核准簽發的《藥品註冊證書》。
根據核准的藥品説明書,公司研發的鹽酸溴己新注射液用於在口服給藥困難的情況下,慢性支氣管炎及其他呼吸道疾病如哮喘、支氣管擴張、矽肺等有粘痰不易咳出的患者。
溴己新具有較強的黏痰溶解作用。主要作用於氣管、支氣管黏膜的黏液產生細胞,抑制痰液中酸性黏多糖蛋白的合成,並可使痰中的黏蛋白纖維斷裂,因此使氣管、支氣管分泌的流變學特徵恢復正常,黏痰減少,痰液稀釋易於咳出。目前,溴己新被國內外眾多權威臨牀指南、專家共識及臨牀路徑釋義所收錄和推薦。
公司獲批的鹽酸溴己新注射液是國內按化學藥品新註冊分類申報,視同通過一致性評價。據米內網數據,2020年國內城市公立和縣級公立醫院溴己新年度銷售約12.50億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.